#Hong Kong #Alzheimer's #Neuraceq #St. Teresa's

Neuraceq® Set to Transform Alzheimer's Diagnosis in Hong Kong

In a significant advancement for Alzheimer's disease (AD) management, Life Molecular Imaging (LMI) has announced that their innovative radioactive diagnostic agent, Florbetaben (18F) Injection, branded as Neuraceq®, will be made available at St. Teresa's Hospital in Hong Kong starting in March 2025. This groundbreaking product aims to reshape the landscape of early Alzheimer's diagnosis and thus enhance patient care standards in the region.

Neuraceq® is FDA-approved and designed for the visualization of amyloid plaques in the brains of patients exhibiting cognitive impairment. These plaques are indicative of Alzheimer’s and are critical when healthcare providers assess patients for this debilitating condition. Through this launch, patients and healthcare professionals in Hong Kong will gain access to advanced diagnostic tools necessary for the accurate and timely identification of Alzheimer's disease, which remains a growing concern in the region.

The introduction of Neuraceq® marks a pivotal moment in LMI’s mission to broaden global availability and access to cutting-edge diagnostic technologies. Ludger Dinkelborg, Ph.D., Managing Director at LMI, expressed enthusiasm about the partnership with St. Teresa’s Hospital, stating, “We are dedicated to ensuring Neuraceq® remains readily available for physicians in the region, enhancing the diagnosis of patients undergoing evaluation for mild cognitive impairment and Alzheimer's disease.